# A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

> **NCT00882908** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 386 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** TMC435
- **DRUG:** Ribavirin (R)
- **DRUG:** PegIFNα-2a (P)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00882908
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-04
- **Final completion:** 2011-04
- **Target enrollment:** 386 (ACTUAL)
- **Last updated:** 2014-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00882908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00882908, "A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00882908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*